4-methyl-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-3-[(5-(5-pyrimidyl)-2-thienyl)methyl]benzene | 842133-96-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-methyl-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-3-[(5-(5-pyrimidyl)-2-thienyl)methyl]benzene
• 英文别名: 1-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)-4-methyl-3-(5 (5-pyrimidinyl)-2-thienylmethyl)benzene；[(2R,3R,4R,5S,6S)-3,4,5-triacetyloxy-6-[4-methyl-3-[(5-pyrimidin-5-ylthiophen-2-yl)methyl]phenyl]oxan-2-yl]methyl acetate
• CAS: 842133-96-4
• 化学式: C₃₀H₃₂N₂O₉S
• 分子量: 596.658
• InChiKey: QLQDASDTOLARLE-JURZQKOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  168
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  4-methyl-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-3-[(5-(5-pyrimidyl)-2-thienyl)methyl]benzene 在 sodium methylate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 以86%的产率得到1-(β-D-glucopyranosyl)-4-methyl-3-[(5-(5-pyrimidyl)-2-thienyl)methyl]benzene
  参考文献：
  名称：

  C-葡萄糖苷与杂芳基噻吩作为新型钠依赖性葡萄糖共转运蛋白2抑制剂

  摘要：

  Canagliflozin（1）是钠依赖性葡萄糖共转运蛋白2（SGLT2）的新型抑制剂，已开发用于治疗2型糖尿病。为了研究替换苯环中的效果1与杂芳族化合物，c ^ -glucosides 2设计，合成，并评价它们对SGLT2抑制活性。其中，3-吡啶基，2-嘧啶基或5-元杂芳基取代的衍生物显示出对SGLT2的强抑制活性，而5-嘧啶基取代与活性略有降低。特别是2g（TA-3404）在高脂饮食喂养的KK（HF-KK）小鼠中具有显着的降血糖作用。

  DOI：

  10.1016/j.bmc.2013.05.048
• 作为产物：
  描述：

  2-甲基-5-溴苯甲酸 在 吡啶 、 三乙基硅烷 、 4-二甲氨基吡啶 、 aluminum (III) chloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 正丁基锂 、 草酰氯 、 甲烷磺酸 、 三氟化硼乙醚 、 N,N-二甲基甲酰胺 、 cesium fluoride 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 二氯甲烷 、 氯仿 、 甲苯 、 乙腈 为溶剂， 反应 7.75h， 生成 4-methyl-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-3-[(5-(5-pyrimidyl)-2-thienyl)methyl]benzene
  参考文献：
  名称：

  C-葡萄糖苷与杂芳基噻吩作为新型钠依赖性葡萄糖共转运蛋白2抑制剂

  摘要：

  Canagliflozin（1）是钠依赖性葡萄糖共转运蛋白2（SGLT2）的新型抑制剂，已开发用于治疗2型糖尿病。为了研究替换苯环中的效果1与杂芳族化合物，c ^ -glucosides 2设计，合成，并评价它们对SGLT2抑制活性。其中，3-吡啶基，2-嘧啶基或5-元杂芳基取代的衍生物显示出对SGLT2的强抑制活性，而5-嘧啶基取代与活性略有降低。特别是2g（TA-3404）在高脂饮食喂养的KK（HF-KK）小鼠中具有显着的降血糖作用。

  DOI：

  10.1016/j.bmc.2013.05.048

文献信息

• [EN] NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER<br/>[FR] NOUVEAUX COMPOSES POSSEDANT UNE ACTIVITE INHIBITRICE DIRIGEE CONTRE LE TRANSPORTEUR DEPENDANT DU SODIUM
  申请人：TANABE SEIYAKU CO

  公开号：WO2005012326A1

  公开（公告）日：2005-02-10

  A compound of the formula (I) wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is -(CH2)n- (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  化合物的式子（I）其中环A和环B为：（1）环A是可选取代的不饱和单环杂环，环B是可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A是可选取代的苯环，环B是可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或（3）环A是可选取代的不饱和融合杂双环，环B独立地是可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是碳原子或氮原子；Y是-(CH2)n-（n为1或2）；其药物可接受的盐或前药。
• Novel compounds
  申请人：Nomura Sumihiro

  公开号：US20050233988A1

  公开（公告）日：2005-10-20

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物，其化学式为：其中环A和环B分别为：（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环；或（3）环A为可选取代的不饱和融合杂双环，环B独立地为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—（CH2）n—（n为1或2）；其药学上可接受的盐或其前药。
• GLUCOPYRANOSIDE COMPOUND
  申请人：NOMURA Sumihiro

  公开号：US20120258913A1

  公开（公告）日：2012-10-11

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物的公式：其中环A和环B是：(1) 环A是一个可选取代的不饱和单环杂环，环B是一个可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，(2) 环A是一个可选取代的苯环，环B是一个可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或(3) 环A是一个可选取代的不饱和融合杂双环，环B是独立的可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是一个碳原子或氮原子；Y是—(CH2)n—(n为1或2)；或其药学上可接受的盐或前药。
• Glucopyranoside compound
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08202984B2

  公开（公告）日：2012-06-19

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的化学式为：其中环A和环B分别为：（1）环A是可选取代的不饱和单环杂环，环B是可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A是可选取代的苯环，环B是可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或（3）环A是可选取代的不饱和融合杂双环，环B是独立的可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是碳原子或氮原子；Y是—(CH2)n—（n为1或2）；或其药学上可接受的盐或前药。
• Novel compounds having inhibitory activity against sodium-dependant glucose transporter
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2514756A1

  公开（公告）日：2012-10-24

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is ―(CH2)n-(n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  式中的化合物： 其中环 A 和环 B 是(1) 环 A 是被任选取代的不饱和单环杂环，环 B 是被任选取代的不饱和单环杂环、被任选取代的不饱和融合杂环或被任选取代的苯环环 B 是任选取代的不饱和单环杂环或任选取代的不饱和融合杂环，或 (3) 环 A 是任选取代的不饱和融合杂环，环 B 独立地是任选取代的不饱和单环杂环、任选取代的不饱和融合杂环或任选取代的苯环；X 是碳原子或氮原子； Y 是-(CH2)n-(n 是 1 或 2)； 其药学上可接受的盐，或其原药。